The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-30

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effectiveness of treatment with Circadin based on sleep improvement as assessed by the modified Questionnaire Scoring Subjective Characteristics of Sleep before and after the treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs

NCT00816673

Primary Insomnia

COMPLETED PHASE2

Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

NCT00397189

Primary Insomnia

COMPLETED PHASE3

Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study

NCT02836743

REM Sleep Behavior Disorder

UNKNOWN PHASE4

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

NCT02841709

Insomnia Disorder

COMPLETED PHASE2

Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients

NCT01450228

Sleep Initiation and Maintenance Disorders

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insomnia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients aged ≥ 55 years suffering from non-organic insomnia according to International Classification of Diseases (ICD-10)
* Patients with sleep disorders manifested as poor sleep quality associated with impaired daytime functioning with or without one or more of the following criteria: difficulty falling asleep, frequent night awakenings, early morning awakenings
* Patients able to follow the study protocol
* Patients who have signed the Informed Consent prior to initiation of any observation-related procedures
* Patients with a global score of ≤17 inclusively on the modified Questionnaire Scoring Subjective Characteristics of Sleep
* Patients who have just been identified to receive treatment with Circadin
* Patients without previous treatment with Circadin

Exclusion Criteria

* Hypersensitivity to any components of Circadin
* Congenital galactose intolerance, glucose-galactose malabsorption, Lapp lactase deficiency
* Pregnancy and lactation
* Alcohol or drug addiction
* Severe somatic and neurological conditions, exacerbations thereof, including autoimmune diseases or renal/hepatic insufficiency
* Intake of psychoactive medicines within the last 30 days before observational study entry
* Presence of clinically significant anxiety and depression as assessed by the Hospital Anxiety and Depression Scale
* Presence of pain that might be the cause for insomnia. Subjects suffering from breathing related sleep disorders

Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No